BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Rathnam Chaguturu Joins SRI International's Center for Advanced Drug Research as Senior Director of Exploratory Research


1/26/2012 9:32:11 AM

MENLO PARK, Calif., Jan. 25, 2012 /PRNewswire/ -- Rathnam Chaguturu, Ph.D., has joined SRI International's Center for Advanced Drug Research (CADRE) as senior director of Exploratory Research. He will be based at SRI Shenandoah Valley in Harrisonburg, Virginia. In this role, Dr. Chaguturu will partner with SRI's drug discovery and development teams and expand collaborative research relationships with academia, disease foundations, nonprofits, and government agencies.

"I am pleased to welcome Dr. Chaguturu to SRI International," said Krishna Kodukula, Ph.D., executive director and site head of CADRE in SRI Biosciences. "His initial areas of focus include providing access to new chemical libraries, working with specific disease foundations, and helping to bridge the gap between academic and pharmaceutical industry research through sponsored research."

Prior to joining SRI, Dr. Chaguturu was director of High Throughput Screening Laboratory at the University of Kansas. He played a key role in securing government, commercial, and foundation funding to establish new research programs. He helped to build a drug discovery pipeline of novel therapeutic targets of interest in both common and neglected diseases.

Prior to his work in Kansas, Dr. Chaguturu was director of Drug Discovery at Sierra Sciences, focusing on anti-aging research. In addition, he led discovery research efforts at FMC Corporation for more than 20 years, where he focused on ion channel, receptor, enzyme, and cell-based targets, and was instrumental in designing the industry-first Zymark robotic screening platform for lead discovery.

Earlier in his career, Dr. Chaguturu was on the biochemistry faculty at Rutgers University. While a project leader at Dow Chemical Company, Chaguturu established the early principles of chemical library screening for lead discovery and developed tools for mining in-house chemistry archives.

Dr. Chaguturu has authored more than 50 research publications and holds 11 U.S. patents. He is editor-in-chief of the journal Combinatorial Chemistry and High Throughput Screening. Dr. Chaguturu is also one of the founding members of the Society for Biomolecular Sciences and the founding president of the International Chemical Biology Society. He received his Ph.D. in plant biochemistry from SV University in Tirupati, India.

About SRI's Center for Advanced Drug Research (CADRE)
SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE's mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI's well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.

About SRI's Biosciences Division
SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®from initial discovery to the start of human clinical trialsand specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Silicon Valley-based SRI International, a nonprofit research and development organization, performs sponsored R&D for governments, businesses, and foundations. SRI brings its innovations to the market- place through technology licensing, new products, and spin-off ventures. SRI is known for world-changing innovations in computing, health and pharmaceuticals, chemistry and materials, sensing, energy, education, national defense, and more.

SOURCE SRI International



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES